Virios Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Virios Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Virios Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 13.3 %, a 3.05% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 13.3 -0.42 -3.05% Jun 30, 2024
Q1 2024 12.2 -5.11 -29.6% Mar 31, 2024
Q4 2023 9.96 -8.81 -46.9% Dec 31, 2023
Q3 2023 11.4 -4.66 -29% Sep 30, 2023
Q2 2023 13.8 +1.5 +12.2% Jun 30, 2023
Q1 2023 17.3 +9.37 +119% Mar 31, 2023
Q4 2022 18.8 +13.3 +242% Dec 31, 2022
Q3 2022 16.1 +11.2 +229% Sep 30, 2022
Q2 2022 12.3 Jun 30, 2022
Q1 2022 7.9 Mar 31, 2022
Q4 2021 5.49 Dec 31, 2021
Q3 2021 4.89 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.